|
1.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2.
|
Ibrahim T, Mercatali L, Casadei R and
Sabbatini R: Clinical manifestation. Osteoncology textbook. Amadori
D, Cascinu S, Conte P and Ibrahim T: Poletto editore; Milan: pp.
258–276. 2010
|
|
3.
|
Søgaard KK, Cronin-Fenton DP, Pedersen L,
Sørensen HT and Lash TL: Survival in Danish patients with breast
cancer and inflammatory bowel disease: a nationwide cohort study.
Inflamm Bowel Dis. 14:519–525. 2008.PubMed/NCBI
|
|
4.
|
Louwman WJ, Voogd AC, van Dijck JA,
Nieuwenhuijzen GA, Ribot J, Pruijt JF and Coebergh JW: On the
rising trends of incidence and prognosis for breast cancer patients
diagnosed 1975–2004: a long-term population-based study in
southeastern Netherlands. Cancer Causes Control. 19:97–106.
2008.
|
|
5.
|
Coleman RE and Rubens RD: The clinical
course of bone metastases from breast cancer. Br J Cancer.
55:61–66. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Chambers AF, Groom AC and MacDonald IC:
Dissemination and growth of cancer cells in metastatic sites. Nat
Rev Cancer. 2:563–572. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Blanco MA and Kang Y: Signaling pathways
in breast cancer metastasis - novel insights from functional
genomics. Breast Cancer Res. 13:2062011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Fidler IJ: The pathogenesis of cancer
metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003.
|
|
9.
|
Kang Y: New tricks against an old foe:
molecular dissection of metastasis tissue tropism in breast cancer.
Breast Dis. 26:129–138. 2007.PubMed/NCBI
|
|
10.
|
Buijs JT and van der Pluijm G: Osteotropic
cancers: from primary tumor to bone. Cancer Lett. 273:177–193.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Sethi N and Kang Y: Unravelling the
complexity of metastasis - molecular understanding and targeted
therapies. Nat Rev Cancer. 11:735–748. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Santini D, Schiavon G, Vincenzi B, et al:
Receptor activator of NF-κB (RANK) expression in primary tumors
associates with bone metastasis occurrence in breast cancer
patients. PLoS One. 6:e192342011.
|
|
13.
|
Ibrahim T, Sacanna E, Gaudio M, et al:
Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting
bone metastases in breast cancer patients. Clin Breast Cancer.
11:369–375. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Virk MS and Lieberman JR: Tumor metastasis
to bone. Arthritis Res Ther. 9(Suppl 1): S52007. View Article : Google Scholar
|
|
15.
|
Boyle WJ, Simonet WS and Lacey DL:
Osteoclast differentiation and activation. Nature. 423:337–342.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Roodman GD: Mechanisms of bone metastasis.
N Engl J Med. 350:1655–1664. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Weinfurt KP, Li Y, Castel LD, Saad F, et
al: The significance of skeletal-related events for the
health-related quality of life of patients with metastatic prostate
cancer. Ann Oncol. 16:579–584. 2005. View Article : Google Scholar
|
|
18.
|
Saad F, Lipton A, Cook R, Chen YM, Smith M
and Coleman R: Pathologic fractures correlate with reduced survival
in patients with malignant bone disease. Cancer. 110:1860–1867.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Delea T, McKiernan J, Brandman J, et al:
Retrospective study of the effect of skeletal complications on
total medical care costs in patients with bone metastases of breast
cancer seen in typical clinical practice. J Support Oncol.
4:341–347. 2006.
|
|
20.
|
Jensen AØ, Jacobsen JB, Nørgaard M, Yong
M, Fryzek JP and Sørensen HT: Incidence of bone metastases and
skeletal-related events in breast cancer patients: a
population-based cohort study in Denmark. BMC Cancer.
11:292011.
|
|
21.
|
Dent R, Hanna WM, Trudeau M, Rawlinson E,
Sun P and Narod SA: Pattern of metastatic spread in triple-negative
breast cancer. Breast Cancer Res Treat. 115:423–428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Hortobagyi GN, Theriault RL, Lipton A, et
al: Long-term prevention of skeletal complications of metastatic
breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer
Study Group J Clin Oncol. 16:2038–2044. 1998.PubMed/NCBI
|
|
23.
|
Hortobagyi GN, Theriault RL, Porter L, et
al: Efficacy of pamidronate in reducing skeletal complications in
patients with breast cancer and lytic bone metastases. Protocol 19
Aredia Breast Cancer Study Group N Engl J Med. 335:1785–1791.
1996.PubMed/NCBI
|
|
24.
|
Domchek SM, Younger J, Finkelstein DM and
Seiden MV: Predictors of skeletal complications in patients with
metastatic breast carcinoma. Cancer. 89:363–368. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Cazzaniga ME, Dogliotti L, Cascinu S, et
al: Diagnosis, management and clinical outcome of bone metastases
in breast cancer patients: results from a prospective, multicenter
study. Oncology. 71:374–381. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Koizumi M, Yoshimoto M, Kasumi F and Ogata
E: Comparison between solitary and multiple skeletal metastatic
lesions of breast cancer patients. Ann Oncol. 14:1234–1240. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Niikura N, Liu J, Hayashi N, et al:
Treatment outcome and prognostic factors for patients with
bone-only metastases of breast cancer: a single-institution
retrospective analysis. Oncologist. 16:155–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Johnston SR: The role of chemotherapy and
targeted agents in patients with metastatic breast cancer. Eur J
Cancer. 47(Suppl 3): S38–S47. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Cruz Jurado J, Richart Aznar P, García
Mata J, et al: Management of patients with metastatic breast
cancer. Adv Ther. 28(Suppl 6): 50–65. 2011.
|
|
30.
|
El Saghir NS, Tfayli A, Hatoum HA, Nachef
Z, Dinh P and Awada A: Treatment of metastatic breast cancer:
state-of-the-art, subtypes and perspectives. Crit Rev Oncol
Hematol. 80:433–449. 2011.
|
|
31.
|
Lipton A: Implications of bone metastases
and the benefits of bone-targeted therapy. Semin Oncol. 37(Suppl
2): S15–S29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Pagani O, Senkus E, Wood W, et al ESO-MBC
Task Force: International guidelines for management of metastatic
breast cancer: can metastatic breast cancer be cured? J Natl Cancer
Inst. 102:456–463. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Amadori A, Cascinu S, Conte PF and Ibrahim
T: Osteo-oncology Textbook. Poletto Editore; Milan: pp. 5862010
|
|
34.
|
Ibrahim T, Flamini E, Fabbri L, et al:
Multidisciplinary approach to the treatment of bone metastases:
Osteo-Oncology Center, a new organizational model. Tumori.
95:291–297. 2009.PubMed/NCBI
|
